This study looked at patients with non-muscle-invasive bladder cancer. Researchers compared giving bacillus calmette-guerin plus mitomycin against giving bacillus calmette-guerin by itself. The goal was to see if adding the second drug helped keep the cancer from coming back or getting worse.
After forty-eight months of follow-up, results showed no clear benefit. The chance of staying free from disease was similar for both groups. About three-quarters of patients in each group remained disease-free after two years. Adding mitomycin did not lower the risk of the cancer returning or spreading.
However, the combined treatment required more total doses of bacillus calmette-guerin. Patients also experienced more severe side effects when getting both drugs. Despite these downsides, fewer patients stopped treatment early in the combined group. This suggests the mix might be a useful option if bacillus calmette-guerin runs short.
The main takeaway is that adding mitomycin does not improve survival. It also increases side effects and uses more of the main drug. Doctors should consider these factors when choosing a treatment plan for their patients.